467 related articles for article (PubMed ID: 27647168)
1. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.
Camm AJ; Accetta G; Ambrosio G; Atar D; Bassand JP; Berge E; Cools F; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Kayani G; Koretsune Y; Mantovani LG; Misselwitz F; Oh S; Turpie AG; Verheugt FW; Kakkar AK;
Heart; 2017 Feb; 103(4):307-314. PubMed ID: 27647168
[TBL] [Abstract][Full Text] [Related]
2. Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry.
Apenteng PN; Gao H; Hobbs FR; Fitzmaurice DA;
BMJ Open; 2018 Jan; 8(1):e018905. PubMed ID: 29331969
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry.
Cools F; Wollaert B; Vervoort G; Verstraete S; Voet J; Hermans K; Heyse A; De Wolf A; Hollanders G; Boussy T; Anné W; Vercammen J; Faes D; Beutels M; Mairesse G; Purnode P; Blankoff I; Vandergoten P; Capiau L; Allu J; Bassand JP; Kayani G;
Acta Cardiol; 2019 Aug; 74(4):309-318. PubMed ID: 30369290
[No Abstract] [Full Text] [Related]
5. Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II.
Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma C; Zint K; Elsaesser A; Bartels DB; Lip GY;
Am J Med; 2015 Dec; 128(12):1306-13.e1. PubMed ID: 26239094
[TBL] [Abstract][Full Text] [Related]
6. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
[TBL] [Abstract][Full Text] [Related]
7. Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends.
Shiyovich A; Shalev V; Chodick G; Tirosh M; Katz A; Klar MM; Shuvy M; Pereg D; Minha S
BMC Cardiovasc Disord; 2021 Oct; 21(1):493. PubMed ID: 34645389
[TBL] [Abstract][Full Text] [Related]
8. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2.
Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Bartels DB; Lip GY;
J Am Coll Cardiol; 2017 Feb; 69(7):777-785. PubMed ID: 28209218
[TBL] [Abstract][Full Text] [Related]
9. Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study.
Krittayaphong R; Winijkul A; Methavigul K; Wongtheptien W; Wongvipaporn C; Wisaratapong T; Kunjara-Na-Ayudhya R; Boonyaratvej S; Komoltri C; Kaewcomdee P; Yindeengam A; Sritara P;
BMC Cardiovasc Disord; 2018 Aug; 18(1):174. PubMed ID: 30144802
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Kerschnitzki M; Reimitz PE; Kirchhof P;
BMC Cardiovasc Disord; 2019 Jul; 19(1):165. PubMed ID: 31299906
[TBL] [Abstract][Full Text] [Related]
11. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.
Martinez C; Katholing A; Wallenhorst C; Freedman SB
Thromb Haemost; 2016 Jan; 115(1):31-9. PubMed ID: 26246112
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Adherence to Guideline-Directed Antithrombotic Therapy for Atrial Fibrillation at Hospital Discharge.
Dupree L; DeLosSantos M; Smotherman C
J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):502-508. PubMed ID: 29806486
[TBL] [Abstract][Full Text] [Related]
13. Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study.
Renoux C; Coulombe J; Suissa S
BMC Cardiovasc Disord; 2016 May; 16():84. PubMed ID: 27160254
[TBL] [Abstract][Full Text] [Related]
14. Stroke prevention in patients from Latin American countries with non-valvular atrial fibrillation: Insights from the GARFIELD-AF registry.
Jerjes-Sanchez C; Corbalan R; Barretto ACP; Luciardi HL; Allu J; Illingworth L; Pieper KS; Kayani G;
Clin Cardiol; 2019 May; 42(5):553-560. PubMed ID: 30873623
[TBL] [Abstract][Full Text] [Related]
15. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.
Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L
J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375
[TBL] [Abstract][Full Text] [Related]
16. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II).
Steinberg BA; Shrader P; Pieper K; Thomas L; Allen LA; Ansell J; Chan PS; Ezekowitz MD; Fonarow GC; Freeman JV; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli GV; Reiffel JA; Singer DE; Peterson ED; Piccini JP;
J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29453305
[TBL] [Abstract][Full Text] [Related]
17. The Tasmanian atrial fibrillation study: Transition to direct oral anticoagulants 2011-2015.
Alamneh EA; Chalmers L; Bereznicki LR
Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28177198
[TBL] [Abstract][Full Text] [Related]
18. Discrepancy between guidelines for stroke prevention in atrial fibrillation and practice patterns in primary care. The nationwide French AFIGP survey.
Sabouret P; Bricard M; Hermann MA; Cotté FE; Deret-Bixio L; Rushton-Smith S
Arch Cardiovasc Dis; 2015 Nov; 108(11):544-53. PubMed ID: 26113478
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation.
Bassand JP; Accetta G; Al Mahmeed W; Corbalan R; Eikelboom J; Fitzmaurice DA; Fox KAA; Gao H; Goldhaber SZ; Goto S; Haas S; Kayani G; Pieper K; Turpie AGG; van Eickels M; Verheugt FWA; Kakkar AK;
PLoS One; 2018; 13(1):e0191592. PubMed ID: 29370229
[TBL] [Abstract][Full Text] [Related]
20. Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: results from the First European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA).
Potpara TS; Larsen TB; Deharo JC; Rossvoll O; Dagres N; Todd D; Pison L; Proclemer A; Purefellner H; Blomström-Lundqvist C;
Europace; 2015 Jun; 17(6):986-93. PubMed ID: 26023177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
